BulBio is the only State-Owned Enterprise (SOE) in Bulgaria and its roots started more than 130 years ago. Nonetheless, as a trade company, it was legally established back in 2000 since before that year the company was in the same organization with the National Institute of Infectious and Parasite Diseases. Currently, BulBio is more in charge of the manufacturing capabilities while the National Institute of Infectious and Parasite Diseases manages the scientific development of existing and new drugs.
The company offers a broad array of solutions such as vaccines, immunostimulators, human blood products, allergens, and diagnostic preparations to target different therapeutic areas like diphtheria, tetanus, among others. However, its unique positioning is within the vaccines’ arena with its BCG vaccine, which is recognized as a golden standard globally and it targets tuberculosis. Indeed, there are only four players in the globe that produce this vaccine being BulBio one of them.
Looking ahead, we are closely working with our scientific team in order to continue expanding our portfolio in other areas such as multi vaccines and immunoprofilaxi medicines.
Contact
Address: 26 Yanko Sakazov Blvd., 1504 Sofia, Bulgaria.
Tel. +359 2 944 61 91
Website: http://www.bulbio.com
Kalin Tochev, country manager of IQVIA Bulgaria, discusses the main trends taking place in the Bulgarian pharmaceutical sector and highlights the end-to-end approach that IQVIA offers to its clients to…
Clinical research is one of the main areas of investment from research-based pharmaceutical companies into Bulgaria and the country is positioning itself as a clinical trials hub for the entire…
Krassimira Chemishanska, president of AmCham Bulgaria, highlights the opportunities Bulgaria can offer to foreign companies as well as investors and explains the fundamental role of collaboration in the country in…
Zoya Paunova, country director at AstraZeneca Bulgaria, explains how a great combination of an innovative product portfolio with a skilled and dedicated team has turned the local offering into leading…
Hristo Sabev, director of clinical management for PPD in Bulgaria, shares an interesting overview of clinical research in Bulgaria and highlights PPD’s commitment as one of the leading CROs in…
Peter Velev, chairman and CEO at Ecopharm, gives an update of the success of his generics company, Ecopharm, and introduces its new digital platform, Credoweb, created to accompany the pharmaceutical…
Ivan Kolev, country manager at Wörwag Pharma Bulgaria, explains how has the affiliate performed over the last years as well as shares an overview about the development of diabetes and…
Vladimir Afenliev, chief director business operations, strategic and organizational developments at Sopharma, explains the great success of the strongest Bulgarian pharmaceutical company in the country as well as the upcoming…
Yavor Kostov, country manager at Mylan in Bulgaria, discloses his strategies to successfully lead an affiliate through corporate changes and explains the important mission of Mylan to provide high-quality treatments…
Ekaterina Karpuzova, country commercial lead pharmaceuticals at Bayer Bulgaria, explains how the national healthcare system has evolved over the last few years as well as demonstrates the commitment of Bayer…
Ana Tsakova, managing director at Merck Bulgaria, emphasizes the duty of the industry to raise the bar of treatment quality in the country and shows the commitment of Merck in…
Jeroen Weites, South-East Europe Cluster head General Medicines and country chair Bulgaria at Sanofi, gives an overview of the company’s leadership in the country and highlights the urgency of developing…
See our Cookie Privacy Policy Here
